# Suzanne E Schindler

## List of Publications by Year
in descending order

| | | | |
|---|---|---|---|
| **57**<br>papers | **2,425**<br>citations | 279798<br>**23**<br>h-index | 223800<br>**46**<br>g-index |
| **57**<br>all docs | **57**<br>docs citations | **57**<br>times ranked | **3216**<br>citing authors |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1 | Comparative analytical performance of multiple plasma A$\beta$42 and A$\beta$40 assays and their ability to predict positron emission tomography amyloid positivity. Alzheimer's and Dementia, 2023, 19, 956-966. | 0.8 | 24 |
| 2 | Network dysfunction in cognitively normal <i>APOE</i> $\epsilon$4 carriers is related to subclinical tau. Alzheimer's and Dementia, 2022, 18, 116-126. | 0.8 | 7 |
| 3 | Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage. Neurobiology of Disease, 2022, 166, 105662. | 4.4 | 21 |
| 4 | A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer's disease. Brain Communications, 2022, 4, fcac045. | 3.3 | 17 |
| 5 | Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults. Alzheimer's and Dementia, 2022, 18, 2570-2581. | 0.8 | 8 |
| 6 | Sex-Specific Patterns of Body Mass Index Relationship with White Matter Connectivity. Journal of Alzheimer's Disease, 2022, 86, 1831-1848. | 2.6 | 7 |
| 7 | Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, . | 6.0 | 16 |
| 8 | Adverse driving behaviors are associated with sleep apnea severity and age in cognitively normal older adults at risk for Alzheimer's disease. Sleep, 2022, 45, . | 1.1 | 7 |
| 9 | Validation of Plasma Amyloid-$\beta$ 42/40 for Detecting Alzheimer Disease Amyloid Plaques. Neurology, 2022, 98, . | 1.1 | 89 |
| 10 | Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease. NeuroImage, 2022, 256, 119228. | 4.2 | 27 |
| 11 | Effect of Race on Prediction of Brain Amyloidosis by Plasma A$\beta$42/A$\beta$40, Phosphorylated Tau, and Neurofilament Light. Neurology, 2022, 99, . | 1.1 | 63 |
| 12 | Predicting Symptom Onset in Sporadic Alzheimer's Disease: "How Long Do I Have?" Journal of Alzheimer's Disease, 2022, , 1-5. | 2.6 | 1 |
| 13 | Fluid Biomarkers in Dementia Diagnosis. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 822-833. | 0.8 | 6 |
| 14 | <scp>ANA</scp> Investigates: The Future of Biomarkers in Alzheimer Disease. Annals of Neurology, 2022, 92, 159-160. | 5.3 | 0 |
| 15 | Socioeconomic Status Mediates Racial Differences Seen Using the <scp>AT(N)</scp> Framework. Annals of Neurology, 2021, 89, 254-265. | 5.3 | 42 |
| 16 | Combining blood-based biomarkers to predict risk for Alzheimer's disease dementia. Nature Aging, 2021, 1, 26-28. | 11.6 | 20 |
| 17 | Obesity and White Matter Neuroinflammation Related Edema in Alzheimer's Disease Dementia Biomarker Negative Cognitively Normal Individuals. Journal of Alzheimer's Disease, 2021, 79, 1801-1811. | 2.6 | 18 |
| 18 | African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurology: Genetics, 2021, 7, e571. | 1.9 | 27 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 19 | Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity, 2021, 11, 239-249. | 1.7 | 18 |
| 20 | Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease. Neurology, 2021, 97, e76-e87. | 1.1 | 17 |
| 21 | GPS driving: a digital biomarker for preclinical Alzheimer disease. Alzheimer's Research and Therapy, 2021, 13, 115. | 6.2 | 42 |
| 22 | Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25. Neurobiology of Aging, 2021, 102, 64-72. | 3.1 | 7 |
| 23 | Machine learning for modeling the progression of Alzheimer disease dementia using clinical data: a systematic literature review. JAMIA Open, 2021, 4, ooab052. | 2.0 | 44 |
| 24 | Falls: a marker of preclinical Alzheimer disease: a cohort study protocol. BMJ Open, 2021, 11, e050820. | 1.9 | 8 |
| 25 | Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology, 2021, 97, e1823-e1834. | 1.1 | 35 |
| 26 | Racial differences in Alzheimer biomarkers among early-stage symptomatic and cognitively normal Alzheimer Disease Research Center (ADRC) participants. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 0 |
| 27 | Presence of co-pathology in sporadic early-onset Alzheimer disease versus dominantly inherited Alzheimer disease. Alzheimer's and Dementia, 2021, 17, e055045. | 0.8 | 0 |
| 28 | COVID-19 and preclinical Alzheimer disease: Driving, mobility, activity and experiences of older adults in the United States. Alzheimer's and Dementia, 2021, 17, e057692. | 0.8 | 2 |
| 29 | Addressing Health Disparities Among Minority Populations. JAMA Neurology, 2020, 77, 1063. | 9.0 | 60 |
| 30 | Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. Journal of Alzheimer's Disease, 2020, 76, 27-31. | 2.6 | 8 |
| 31 | Resting State Functional Connectivity Signature Differentiates Cognitively Normal from Individuals Who Convert to Symptomatic Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 74, 1085-1095. | 2.6 | 18 |
| 32 | Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 74, 1119-1129. | 2.6 | 14 |
| 33 | High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology, 2019, 93, e1647-e1659. | 1.1 | 514 |
| 34 | Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 1149-1159. | 0.8 | 45 |
| 35 | Association of Acquired and Heritable Factors With Intergenerational Differences in Age at Symptomatic Onset of Alzheimer Disease Between Offspring and Parents With Dementia. JAMA Network Open, 2019, 2, e1913491. | 5.9 | 11 |
| 36 | Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 655-665. | 0.8 | 72 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 37 | ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology, 2019, 92, e1567-e1579. | 1.1 | 73 |
| 38 | Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. JAMA Network Open, 2019, 2, e1917126. | 5.9 | 23 |
| 39 | Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. JAMA Neurology, 2019, 76, 264. | 9.0 | 227 |
| 40 | Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimer's and Dementia, 2018, 14, 1460-1469. | 0.8 | 192 |
| 41 | Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline. Journal of Alzheimer's Disease, 2018, 62, 745-756. | 2.6 | 45 |
| 42 | Upward drift in cerebrospinal fluid amyloid Î² 42 assay values for more than 10Âyears. Alzheimer's and Dementia, 2018, 14, 62-70. | 0.8 | 50 |
| 43 | O3â€‘14â€‘01: NOVEL CSF BIOMARKERS OF NEURONAL INJURY, SYNAPTIC DYSFUNCTION AND NEUROINFLAMMATION IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: VILIPâ€‘1, NEUROGRANIN, SNAPâ€‘25 AND YKLâ€‘40 IN THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN). Alzheimer's and Dementia, 2018, 14, P1059. | 0.8 | 0 |
| 44 | Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. Brain, 2018, 141, 3233-3248. | 7.6 | 24 |
| 45 | Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1505-1521. | 0.8 | 163 |
| 46 | Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia. Neurology, 2018, 91, e436-e443. | 1.1 | 38 |
| 47 | Double Monoclonal Immunoassay for Quantifying Human Visinin-Like Protein-1 in CSF. Clinical Chemistry, 2017, 63, 603-604. | 3.2 | 4 |
| 48 | Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. Neurobiology of Aging, 2017, 56, 25-32. | 3.1 | 57 |
| 49 | Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Science Translational Medicine, 2017, 9, . | 12.4 | 78 |
| 50 | [P3â€"205]: EMERGING CSF BIOMARKERS AS PREDICTORS OF ALZHEIMER DISEASE DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1014. | 0.8 | 0 |
| 51 | [O2â€"05â€"03]: CONCORDANCE BETWEEN CSF AD BIOMARKERS MEASURED BY THE AUTOMATED ELECSYS ASSAY AND <i>IN VIVO</i> AMYLOID IMAGING. Alzheimer's and Dementia, 2017, 13, P561. | 0.8 | 0 |
| 52 | <scp>CSF sTREM</scp> 2: marking the tipping point between preclinical <scp>AD</scp> and dementia?. EMBO Molecular Medicine, 2016, 8, 437-438. | 6.9 | 3 |
| 53 | O1-05-03: Upward Drift in CSf AB42 Values over 10 Years. , 2016, 12, P183-P183. | | 1 |
| 54 | P1-006: Emerging CSF Biomarkers of Neuroinflammation, Neuronal Injury And Synaptic Integrity in the Adni Cohort. , 2016, 12, P399-P399. | | 1 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 55 | Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome. Neurologist, 2016, 21, 112-117. | 0.7 | 58 |
| 56 | Photo-activatable Cre recombinase regulates gene expression in vivo. Scientific Reports, 2015, 5, 13627. | 3.3 | 70 |
| 57 | Advances in diagnostic testing for Alzheimer disease. Missouri Medicine, 2013, 110, 401-5. | 0.3 | 3 |